Fig. 2From: Novel therapeutics in myeloproliferative neoplasmsPositioning of JAK inhibitors in the treatment schema of myelofibrosis. ESA—erythropoiesis-stimulating agent; EMA—erythroid maturation agent; IMiD—immunomodulatory imide drugs; BET—Bromodomain and Extraterminal domain Protein; PI3K—Phosphatidylinositol 3-Kinase; MDM—murine double minute; IDH—isocitrate dehydrogenaseBack to article page